Investor s Fiduciary Advisor Network LLC Takes Position in Bristol-Myers Squibb (NYSE:BMY)

Investor s Fiduciary Advisor Network LLC bought a new stake in shares of Bristol-Myers Squibb (NYSE:BMY) in the 4th quarter, HoldingsChannel.com reports. The firm bought 8,200 shares of the biopharmaceutical company’s stock, valued at approximately $463,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Guardian Wealth Advisors LLC NC raised its position in shares of Bristol-Myers Squibb by 22.2% during the 4th quarter. Guardian Wealth Advisors LLC NC now owns 5,198 shares of the biopharmaceutical company’s stock valued at $294,000 after acquiring an additional 946 shares in the last quarter. Focus Partners Wealth raised its position in shares of Bristol-Myers Squibb by 18.8% during the 4th quarter. Focus Partners Wealth now owns 217,570 shares of the biopharmaceutical company’s stock valued at $12,807,000 after acquiring an additional 34,466 shares in the last quarter. Ellevest Inc. raised its position in shares of Bristol-Myers Squibb by 19.0% during the 4th quarter. Ellevest Inc. now owns 10,394 shares of the biopharmaceutical company’s stock valued at $588,000 after acquiring an additional 1,657 shares in the last quarter. Ethic Inc. raised its position in shares of Bristol-Myers Squibb by 3.6% during the 4th quarter. Ethic Inc. now owns 174,424 shares of the biopharmaceutical company’s stock valued at $9,865,000 after acquiring an additional 6,044 shares in the last quarter. Finally, Farallon Capital Management LLC acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at approximately $180,313,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, EVP Samit Hirawat acquired 1,823 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was purchased at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now directly owns 63,932 shares in the company, valued at $3,506,030.88. The trade was a 2.94% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on BMY shares. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $55.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Jefferies Financial Group dropped their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a research report on Wednesday, April 23rd. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Wells Fargo & Company raised their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a report on Friday, February 7th. Finally, UBS Group lowered their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a report on Friday, April 11th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $58.00.

Bristol-Myers Squibb Trading Down 1.1%

Shares of BMY opened at $46.38 on Monday. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The business’s fifty day moving average is $54.54 and its 200-day moving average is $56.23. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The firm has a market cap of $94.39 billion, a price-to-earnings ratio of -10.49, a PEG ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Bristol-Myers Squibb’s quarterly revenue was down 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($4.40) EPS. Equities analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were paid a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.35%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 92.88%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.